Core Viewpoint - The article discusses the significant advancements in the treatment of nasopharyngeal carcinoma (NPC) through the use of immune therapies like PD-1 inhibitors, highlighting the shift in focus from merely improving efficacy to enhancing safety and quality of life for patients [3][5]. Group 1: Clinical Trial Insights - The PLATINUM trial, a phase 2 clinical study, investigates the combination of nivolumab with chemotherapy and radiotherapy while omitting the traditional concurrent cisplatin treatment, focusing on patient-reported outcomes (PRO) [4][9]. - The study reveals that radiotherapy is the primary cause of decreased quality of life in patients, with specific symptoms such as appetite loss, speech, and swallowing difficulties being critical for assessing disease recurrence and social reintegration [4][10]. Group 2: Patient-Reported Outcomes - The research emphasizes the need for a comprehensive evaluation of cancer treatments that prioritizes patient quality of life alongside efficacy, making patient subjective experiences a key measurement standard [5][8]. - In the trial, 44.1% of the 152 NPC patients achieved social reintegration, and 51.3% reported satisfaction with their current life, indicating a significant impact of treatment on their overall well-being [10]. - The findings suggest that interventions targeting speech, swallowing, and appetite may enhance recovery outcomes for NPC patients, as these factors are linked to successful social reintegration and overall quality of life [10].

Core Viewpoint - The article discusses the promising results of fecal microbiota transplantation (FMT) combined with immunotherapy in treating non-small cell lung cancer (NSCLC), melanoma, and metastatic renal cell carcinoma (mRCC), highlighting its potential to overcome resistance to PD-1 therapy and improve patient outcomes [2][3][4]. Group 1: FMT and Immunotherapy in NSCLC and Melanoma - The FMT-LUMINate trial demonstrated an objective response rate (ORR) of 80% (16/20) in NSCLC and 75% (15/20) in melanoma, achieving the primary endpoint [8]. - Safety assessments indicated no grade 3 or higher adverse events in the NSCLC cohort, while 65% of melanoma patients experienced grade 3 or higher adverse events [8]. - The study found that responders had a unique gut microbiome composition post-FMT, with significant reductions in specific bacterial species associated with non-responders [9]. Group 2: FMT in Metastatic Renal Cell Carcinoma - The PERFORM trial showed that 50% (10/20) of mRCC patients experienced grade 3 immune-related adverse events, with no severe FMT-related toxicities reported [11][14]. - The objective response rate was 50% (9/18), including 11% (2/18) achieving complete response, with most responders not experiencing severe immune-related adverse events [14]. - Improvements in gut microbiome diversity were linked to reduced toxicity and enhanced treatment response, while the presence of specific bacteria correlated with higher immune-related adverse events [15][16]. Group 3: FMT Combined with Pembrolizumab and Axitinib - The TACITO trial evaluated the efficacy of donor-derived FMT in mRCC patients receiving pembrolizumab and axitinib, with a primary endpoint of disease progression-free survival [18][21]. - Although the primary endpoint was not met, the donor FMT group showed a significantly longer median progression-free survival of 24.0 months compared to 9.0 months in the placebo group [22]. - The donor FMT group had an ORR of 52%, while the placebo group had 32%, indicating potential benefits of selective donor FMT in enhancing immunotherapy outcomes [22].

Core Viewpoint - The personalized neoantigen vaccine developed by Dana-Farber Cancer Institute shows significant potential in inducing strong immunity in melanoma patients, although its immunogenicity still requires enhancement [1][2]. Group 1 - The study published in the journal Cell highlights the development of a multi-adjuvant personalized neoantigen vaccine that effectively stimulates immunity in melanoma patients [1][2]. - The research involved testing a long peptide vaccine on 10 melanoma patients, utilizing two adjuvants, Montanide and poly-ICLC, in conjunction with local injection of Ipilimumab and systemic use of Nivolumab [4]. - Among the 9 patients who completed vaccination, the personalized vaccines induced ex vivo T cell responses targeting most neoantigens, with 6 patients generating ex vivo CD8+ T cell responses [5]. Group 2 - Key findings of the study include the ability of most neoantigens to induce ex vivo T cell responses, including CD8+ cell responses [8]. - The vaccine induced dynamic changes in myeloid cell populations at the injection site [8]. - The neoantigen vaccination reshaped the T cell receptor repertoire specific to tumors beyond anti-PD-1 treatment, revealing vaccine-specific tumor-infiltrating lymphocytes (TIL) through TCR reconstruction and antigen screening [8].